comprehensive -WSS

comprehensive

author：leisure time 2025-08-28 13:05:49 - browse：93711

Pascal Soriot 2019 — Pascal Soriot has served as CEO of AstraZeneca since 2012. Win McNamee/Getty Images

CAMBRIDGE, England — On a bit of a roll, AstraZeneca on Tuesday laid out ambitious growth goals for the rest of the decade, seeking to build on its momentum in fields like oncology as it said it would nearly double its revenue to $80 billion by 2030.

Hitting such a target would depend on the launch of 20 new medicines and continued growth of its cancer and rare disease therapies, as well as other drugs. It would also require outpacing the targets laid out by AstraZeneca’s large pharma peers.

But at an investor day here at the company’s shiny new Discovery Centre, CEO Pascal Soriot opened his presentation by bringing up the goal set by the company a decade ago — $45 billion in revenue by 2023. The company faced some declines early in that period, but after surging in the past few years, it hit that target, bringing in $45.8 billion last year. Its recent growth has also propelled the company’s share price.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Testing for cancer recurrence creates a new limbo for patients

entertainment

WSS

FDA rejects Alnylam's heart disease treatment over insufficient data

FDA authorizes Novavax’s updated Covid

Senate panel eyes new effort on drug shortages

AI can decode, harness the power of the humane immune system

Why Sanofi got shellacked over its spinoff

Was Amgen transparent enough on FDA's concern on cancer drug?

knowledge

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

At least 13 dead in Texas as scorching temps continue

Histogen: Failed biotech offers rare public look inside

Hollywood unions extend contract negotiations for actors

WHO may add ‘noma' to its list of neglected tropical diseases

Malaria cases in Florida and Texas: Here’s what you need to know

Eli Lilly to pay $200M for Beam’s stake in gene

Alkermes shareholders re

Physician subsidies by hospitals soar in wake of No Surprises Act

After affirmative action ruling, medical educators look to 'holistic review'

Cassava reveals details — and problems — with Alzheimer's study

knowledge

Bill would stop addiction treatment from triggering child abuse inquiry

WHO may add ‘noma' to its list of neglected tropical diseases

Stroke deaths set to near 10 million globally by 2050

Phenylephrine and the overlooked value of the placebo effect

Physician executives need more than on

Meta's Zuckerberg and Chan on track to put $50 billion into science

entertainment

knowledge

entertainment

Wikipedia